Current controversies in the treatment of HIV infection and AIDS. An economic perspective

PharmacoEconomics

Volumn 10, Issue 2, 1996, Pages 105-108

  Petrou, S ^a  

^a MEDTAP International   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL PRACTICE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHARMACOECONOMICS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0029742130     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610020-00001     Document Type: Short Survey

References (19)

1. 1. JC Borleffs JC Jager 1990 Marinus JJC et al. Hospital costs for patients with HIV infection in a university hospital in the Netherlands Health Policy 16 43 54 10107406 10.1016/0168-8510(90)90440-O 1:STN:280:DyaK3M%2FjsFWgsQ%3D%3D Borleffs JC. Jager JC. Marinus JJC et al. Hospital costs for patients with HIV infection in a university hospital in the Netherlands. Health Policy 1990; 16: 43–54
2. 2. FJ Hellinger 1993 The lifetime cost of treating a person with HIV JAMA 27 4 474 478 10.1001/jama.1993.03510040078033 Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993; 27 (4): 474–478
3. 3. EJ Beck J Kennelly C McKevitt 1994 Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989 AIDS 8 367 377 8031516 10.1097/00002030-199403000-00012 1:STN:280:DyaK2czgsVGmuw%3D%3D Beck EJ. Kennelly J. McKevitt C. et al. Changing use of hospital services and costs at a London AIDS referral centre, 1983-1989. AIDS 1994; 8: 367–377
4. 4. FJ Hellinger JA Fleishman DC Hsia 1994 AIDS treatment costs during the last months of life: evidence from the ACSUS Health Serv Res 29 5 569 581 8002350 1:STN:280:DyaK2M%2FpsFKmtw%3D%3D Hellinger FJ, Fleishman JA. Hsia DC. AIDS treatment costs during the last months of life: evidence from the ACSUS. Health Serv Res 1994; 29 (5): 569–581
5. 5. PG Farnham 1994 Defining and measuring the costs of the HIV epidemic to business firms Public Health Rep 109 3 311 318 8190854 1:STN:280:DyaK2c3kvVarsw%3D%3D Farnham PG. Defining and measuring the costs of the HIV epidemic to business firms. Public Health Rep 1994; 109 (3): 311–318
6. 6. MA Fischl DD Richman DM Causey 1989 Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex JAMA 262 2405 2410 2677429 10.1001/jama.1989.03430170067030 1:STN:280:DyaK3c%2Fht1Ghsg%3D%3D Fischl MA. Richman DD, Causey DM. et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1989; 262: 2405–2410
7. 7. RD Moore J Hidalgo JC Bareta 1994 Zidovudine therapy and health resource utilization in AIDS J Acquir Immune Defic Syndr 4 349 354 Moore RD. Hidalgo J. Bareta JC. et al. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994; (4): 349–354
8. 8. PA Volberding SW Lagakos MA Koch 1990 Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter N Engl J Med 322 941 949 1969115 10.1056/NEJM199004053221401 1:STN:280:DyaK3c7ptVOqtQ%3D%3D Volberding PA. Lagakos SW. Koch MA. et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990: 322: 941–949
9. 9. KA Schulman LA Lynn HA Glick 1991 Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus I HIV) infection Ann Intern Med 11 9 798 802 Schulman KA. Lynn LA. Glick HA. et al. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus I HIV) infection. Ann Intern Med 1991: 11 (9): 798–802
10. 10. JP Aboulker AM Swart 1993 Preliminary analysis of the Concorde trial Lancet 341 889 890 8096582 10.1016/0140-6736(93)93096-J 1:STN:280:DyaK3s3hvVersw%3D%3D Aboulker JP, Swart AM. Preliminary analysis of the Concorde trial. Lancet 1993: 341: 889–890
11. 11. AD Maria 1992 Early versus late treatment with zidovudine N Engl J Med 327 5 359 1620180 10.1056/NEJM199207303270514 [letter] Maria AD. Early versus late treatment with zidovudine [letter]. N Engl J Med 1992; 327 (5): 359
12. 12. AD Paltiel AA Stinnett 1996 AIDS B Spilker Quality of life and pharmacoeconomics in clinical trials Lippincott-Raven Philadelphia 1053 1062 Paltiel AD. Stinnett AA. AIDS. In: Spilker B. editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven. 1996: 1053–1062
13. 13. M Fischl K Stanley AC Collier 1995 Combination and monotherapv with zidovudine and zalcitabine in patients with advanced HIV disease Ann Intern Med 122 24 32 7985892 1:STN:280:DyaK2M%2Fnslaisw%3D%3D Fischl M, Stanley K, Collier AC. et al. Combination and monotherapv with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995; 122: 24–32
14. 14. JO Kahn SW Lagakos DD Richman 1992 A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency vims infection N Engl J Med 327 581 587 1353607 10.1056/NEJM199208273270901 1:STN:280:DyaK38zltVWqsA%3D%3D Kahn JO, Lagakos SW, Richman DD. et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency vims infection. N Engl J Med 1992; 327: 581–587
15. 15. SL Spruance AT Pavia D Peterson 1994 Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine Ann Intern Med 120 360 368 7905722 1:STN:280:DyaK2c7js1ynsw%3D%3D Spruance SL, Pavia AT, Peterson D, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. Ann Intern Med 1994; 120: 360–368
16. 16. Hammer SM, Katzenstein DA, Hughes MD, et al. Virologica markers and outcome in ACTG 175 [abstract S24]. Third Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington DC, 39
17. 17. Gazzard B. Further results from European/Australian Delta trial [abstract LB5a]. Third Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington DC, 86
18. 18. L Mofenson 1994 Epidemiology and determinants of vertical HIV transmission Semin Pediatr Infect Dis 5 252 265 Mofenson L. Epidemiology and determinants of vertical HIV transmission. Semin Pediatr Infect Dis 1994; 5: 252–265
19. 19. EM Connor RS Sperling R Gelber 1994 Reduction of human immunodeficiency virus type 1 with zidovudine treatment N Engl J Med 331 18 1173 1180 7935654 10.1056/NEJM199411033311801 1:STN:280:DyaK2M%2FitFGmuw%3D%3D Connor EM, Sperling RS, Gelber R, et al. Reduction of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331 (18): 1173–1180